UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
or
FOR THE TRANSITION PERIOD FROM __________ TO __________
COMMISSION FILE NUMBER:
(Name of registrant in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) (Zip Code) |
Issuer’s telephone Number:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether
the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| ☒ | Smaller reporting company | |||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The number of shares of registrant’s common stock outstanding,
as of February 11, 2022 was
SUNHYDROGEN, INC.
INDEX
| Page | ||||
| PART I: FINANCIAL INFORMATION | 1 | |||
| Item 1: | Financial Statements | 1 | ||
| Condensed Balance Sheets | 1 | |||
| Condensed Statements of Operations | 2 | |||
| Condensed Statements of Shareholders’ Deficit | 3 | |||
| Condensed Statements of Cash Flows | 4 | |||
| Notes to the Condensed Financial Statements | 5 | |||
| Item 2: | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 16 | ||
| Item 3: | Quantitative and Qualitative Disclosures About Market Risk | 19 | ||
| Item 4: | Controls and Procedures | 19 | ||
| PART II: OTHER INFORMATION | 20 | |||
| Item 1 | Legal Proceedings | 20 | ||
| Item 1a: | Risk Factors | 20 | ||
| Item 2: | Unregistered Sales of Equity Securities and Use of Proceeds | 20 | ||
| Item 3: | Defaults Upon Senior Securities | 20 | ||
| Item 4: | Mine Safety Disclosures | 20 | ||
| Item 5: | Other Information | 20 | ||
| Item 6: | Exhibits | 20 | ||
| Signatures | 21 | |||
i
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
SUNHYDROGEN, INC.
CONDENSED BALANCE SHEETS
| December 31, 2021 | June 30, 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalent | $ | $ | ||||||
| Marketable securities | ||||||||
| Prepaid expenses | ||||||||
| TOTAL CURRENT ASSETS | ||||||||
| LONG TERM INVESTMENTS | ||||||||
| Marketable securities | ||||||||
| PROPERTY & EQUIPMENT | ||||||||
| Computers and peripherals | ||||||||
| Vehicle | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| NET PROPERTY AND EQUIPMENT | ||||||||
| OTHER ASSETS | ||||||||
| Domain, net of amortization of $ | ||||||||
| Trademark, net of amortization of $ | ||||||||
| Patents, net of amortization of $ | ||||||||
| TOTAL OTHER ASSETS | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Accrued expenses, related party | ||||||||
| Accrued interest on convertible notes | ||||||||
| Derivative liability | ||||||||
| TOTAL CURRENT LIABILITIES | ||||||||
| LONG TERM LIABILITIES | ||||||||
| Convertible promissory notes, net of debt discount of $ | ||||||||
| TOTAL LONG TERM LIABILITIES | ||||||||
| TOTAL LIABILITIES | ||||||||
| COMMIMENTS AND CONTINGENCIES (SEE NOTE 9) | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Preferred Stock, $ | ||||||||
| Common Stock, $ | ||||||||
| Additional Paid in Capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY (DEFICIT) | ( | ) | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these condensed unaudited financial statements
1
SUNHYDROGEN, INC.
CONDENSED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED DECEMBER 30, 2021 AND 2020
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| December 31, 2021 | December 31, 2020 | December 31, 2021 | December 31, 2020 | |||||||||||||
| REVENUE | $ | $ | $ | $ | ||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Selling and Marketing | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Research and development cost | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| TOTAL OPERATING EXPENSES | ||||||||||||||||
| LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| OTHER INCOME/(EXPENSES) | ||||||||||||||||
| Other income | ||||||||||||||||
| Loss on redemption of marketable securities | ( | ) | ( | ) | ||||||||||||
| Loss on settlement of derivative liability | ( | ) | ( | ) | ||||||||||||
| Gain (Loss) on change in derivative liability | ( | ) | ( | ) | ||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| TOTAL OTHER INCOME (EXPENSES) | ( | ) | ( | ) | ||||||||||||
| NET INCOME (LOSS) | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| COMMON STOCK WARRANTS DEEMED DIVIDENDS | ( | ) | ( | ) | ||||||||||||
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| BASIC EARNINGS (LOSS) PER SHARE | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| DILUTED EARNINGS (LOSS) PER SHARE | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING | ||||||||||||||||
| BASIC | ||||||||||||||||
| DILUTED | ||||||||||||||||
The accompanying notes are an integral part of these condensed unaudited financial statements
2
SUNHYDROGEN, INC.
CONDENSED STATEMENTS OF SHAREHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED DECEMBER 30, 2021 AND 2020
| SIX MONTHS ENDED DECEMBER 31, 2020 | ||||||||||||||||||||||||||||
| Additional | ||||||||||||||||||||||||||||
| Preferred stock | Common stock | Paid-in | Accumulated | |||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||
| Balance at June 30, 2020 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Issuance of common stock for cash | - | |||||||||||||||||||||||||||
| Purchase of common stock warrants for cash | - | |||||||||||||||||||||||||||
| Issuance of common stock for conversion of debt and accrued interest | ||||||||||||||||||||||||||||
| Issuance of common stock for services | ||||||||||||||||||||||||||||
| Common stock warrants issued with securities purchase agreement at fair value | - | - | - | |||||||||||||||||||||||||
| Issuance of common stock warrants deemed dividends | - | - | ( | ) | - | |||||||||||||||||||||||
| Common stock and warrants compensation expense | - | - | ||||||||||||||||||||||||||
| Net Loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at December 31, 2020 (unaudited) | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| SIX MONTHS ENDED DECEMBER 31, 2021 | ||||||||||||||||||||||||||||
| Additional | ||||||||||||||||||||||||||||
| Preferred stock | Common stock | Paid-in | Accumulated | |||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||
| Balance at June 30, 2021 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Issuance of common stock for conversion of debt and accrued interest | ( | ) | ||||||||||||||||||||||||||
| Issuance of Series C preferred stock in exchange for fair value of convertible note | ||||||||||||||||||||||||||||
| Stock options redeemed by Company | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Net Income | - | - | ||||||||||||||||||||||||||
| Balance at December 31, 2021 (unaudited) | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||
The accompanying notes are an integral part of these condensed unaudited financial statements
3
SUNHYDROGEN, INC.
CONDENSED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED DECEMBER 30, 2021 AND 2020
(Unaudited)
| Six Months Ended | ||||||||
| December 31, 2021 | December 31, 2020 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net Income (loss) | $ | $ | ( | ) | ||||
| Adjustment to reconcile net income (loss) to net cash (used in) provided by operating activities | ||||||||
| Depreciation & amortization expense | ||||||||
| Stock based compensation expense | ||||||||
| Stock issued for services | ||||||||
| Loss on settlement of debt and derivative | ||||||||
| Net (Gain) Loss on change in derivative liability | ( | ) | ||||||
| Amortization of debt discount recorded as interest expense | ||||||||
| Commissions fees paid through offerings | ||||||||
| Change in assets and liabilities: | ||||||||
| Prepaid expense | ( | ) | ||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses | ||||||||
| Accrued interest on convertible notes | ||||||||
| NET CASH USED IN OPERATING ACTIVITIES | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of marketable securities | ( | ) | ||||||
| Purchase of property and equipment | ( | ) | ||||||
| NET CASH USED IN INVESTING ACTIVITIES: | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from the sale of common stock warrants | - | |||||||
| Redemption of related parties stock options | ( | ) | ||||||
| Net proceeds from common stock purchase agreements | ||||||||
| NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES | ( | ) | ||||||
| NET INCREASE (DECREASE) IN CASH | ( | ) | ||||||
| CASH, BEGINNING OF PERIOD | ||||||||
| CASH, END OF PERIOD | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||||||
| Interest paid | $ | $ | ||||||
| Taxes paid | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS | ||||||||
| Fair value of common stock upon conversion of convertible notes , and accrued interest | $ | $ | ||||||
| Fair value of common stock issued for services | $ | $ | ||||||
| Issuance of common stock purchase warrants deemed dividends | $ | $ | ||||||
| Fair value of preferred stock in exchanged for convertible note | $ | $ | ||||||
| Fair value of derivative liability removed | $ | $ | ||||||
The accompanying notes are an integral part of these condensed unaudited financial statements
4
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL
STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 1. | Basis of Presentation |
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ended June 30, 2022. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended June 30, 2021.
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
This summary of significant accounting policies of SunHydrogen, Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.
Cash and Cash Equivalent
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Marketable Securities
The Company considers corporate bonds (“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating of AAA and BBB.
The bonds have varied due dates and were classified as current and noncurrent, based on to their maturity dates. The bonds are generally valued using quoted prices and are classified in Level 2 of the fair value hierarchy as prices are not always from active markets. We consider our investments held to maturity and we believe there are no other than temporary declines in fair value. Our investments are recorded at historical cost.
Use of Estimates
In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
Property and Equipment
Property and equipment are stated at cost and are depreciated using straight line over its estimated useful lives.
| Computers and peripheral equipment | |
| Vehicle |
The Company recognized depreciation
expense of $
Intangible Assets
The Company has patent applications to protect the inventions and processes behind its proprietary solar-to-hydrogen based technology. Intangible assets that have finite useful lives continue to be amortized over their useful lives.
The Company recognized amortization
expense of $
5
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Net Earnings (Loss) per Share Calculations
Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).
December 31, 2021
For the six months ended December 31,
2021, the Company calculated the dilutive impact of the outstanding stock options of
December 31, 2020
For the six months ended December 31,
2020, the Company calculated the dilutive impact of the outstanding stock options of
Equity Incentive Plan and Stock Options
Equity Incentive Plan
On December 17, 2018, the Board of
Directors approved and adopted the 2019 Equity Incentive Plan (“the Plan”), with
Stock Based Compensation
The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.
Warrant Accounting
The Company accounts for the warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.
6
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL
STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2021, the amounts reported for cash, accrued interest and other expenses, notes payables, convertible notes, and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:
| ● | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. |
| ● | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. |
| ● | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows on December 31, 2021 (See Note 6):
| Total | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
| Assets: | ||||||||||||||||
| Marketable securities measured at fair value | $ | $ | $ | $ | ||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative liabilities measured at fair value | $ | $ | $ | $ | ||||||||||||
The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:
| Balance as of June 30, 2021 | ||||
| Fair value of derivative liability removed | ( | ) | ||
| Gain on change in derivative liability | ( | ) | ||
| Balance as of December 31, 2021 | $ |
Research and Development
Research and development costs are
expensed as incurred. Total research and development costs were $
Accounting for Derivatives
The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.
7
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL
STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Recently Issued Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements as of December 31, 2021.
| 3. | CAPITAL STOCK |
Preferred Stock
On December 15, 2021, the Company filed
a certificate of designation of preferences, right and limitations of Series C Preferred Stock with the Secretary of State of Nevada,
designating
The Company entered into a securities
purchase agreement on December 15, 2021, with an accredited investor for an exchange of convertible debt to equity. The investor exchanged
a convertible note in the amount of $
| Per Valuation | ||||
| Preferred shares issued | $ | |||
| Stated value of debt and interest | $ | |||
| Calculated fair value of preferred shares | $ | |||
| Fair value of derivative liability removed | $ | |||
| Loss on settlement | $ | |||
The Company
recognized a loss on settlement of $
Common Stock
Six months ended December 31, 2021
During the six months ended December
31, 2021, the Company issued
Six months ended December 31, 2020
During the six months ended December
31, 2020, the Company issued
During the six months ended December
31, 2020, the Company issued
8
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL
STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 3. | CAPITAL STOCK (Continued) |
During the six months ended December
31, 2020, the Company issued
During the six months ended December
31, 2020, the Company issued
| 4. | OPTIONS AND WARRANTS |
OPTIONS
As of September 30, 2020,
On January 23, 2019, the Company issued
On January 31, 2019,
A summary of the Company’s stock option activity and related information follows:
| 12/31/21 | 12/31/2020 | |||||||||||||||
| Weighted | Weighted | |||||||||||||||
| Number | average | Number | average | |||||||||||||
| Of | exercise | Of | exercise | |||||||||||||
| Options | price | Options | price | |||||||||||||
| Outstanding, beginning of period | $ | $ | ||||||||||||||
| Granted | $ | $ | ||||||||||||||
| Exercised | ||||||||||||||||
| Buyback of options | ( | ) | $ | ( | ) | |||||||||||
| Outstanding, end of period | $ | $ | ||||||||||||||
| Exercisable at the end of period | $ | $ | ||||||||||||||
During the six months ended December
31, 2021, the Company bought back a total of
9
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL
STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 4. | OPTIONS AND WARRANTS (Continued) |
The weighted average remaining contractual life of options outstanding as of December 31, 2021 and 2020 was as follows:
| 12/31/2021 | 12/31/2020 | |||||||||||||||||||||||||||||
| Exercise Price | Stock Options Outstanding | Stock Options Exercisable | Weighted Average Remaining Contractual Life (years) | Exercise Price | Stock Options Outstanding | Stock Options Exercisable | Weighted Average Remaining Contractual Life (years) | |||||||||||||||||||||||
| $ | $ | |||||||||||||||||||||||||||||
| $ | ||||||||||||||||||||||||||||||
| $ | $ | |||||||||||||||||||||||||||||
| $ | $ | |||||||||||||||||||||||||||||
The stock-based compensation expense
recognized in the statement of operations during the six months ended December 31, 2021 and 2020, related to the granting of these options
was $
WARRANTS
As of December 31, 2021, the Company
had an aggregate of
A summary of the Company’s warrant activity and related information follows for the six months ended December 31, 2021.
| 12/31/21 | ||||||||
| Weighted | ||||||||
| Number | average | |||||||
| Of | exercise | |||||||
| Warrants | price | |||||||
| Outstanding, beginning of period | $ | |||||||
| Granted | ||||||||
| Exercised | ||||||||
| Forfeited/Expired | ||||||||
| Outstanding, end of period | $ | |||||||
| Exercisable at the end of period | $ | |||||||
| 12/31/2021 | |||||||||||||
| Exercise Price | Warrants Outstanding | Warrants Exercisable | Weighted Average Remaining Contractual Life (years) | ||||||||||
| $ | |||||||||||||
| $ | |||||||||||||
| $ | |||||||||||||
At December 31, 2021, the aggregate
intrinsic value of the warrants outstanding was $
10
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 5. | CONVERTIBLE PROMISSORY NOTES |
As of December 31, 2021, the outstanding convertible promissory notes net of debt discount are summarized as follows:
| Convertible Promissory Notes, net of debt discount | $ | |||
| Less current portion | ||||
| Total long-term liabilities | $ |
Maturities of long-term debt for the next five years are as follows:
| Period Ended December 31, | Amount | |||
| 2022 | $ | |||
| 2023 | ||||
| 2024 | ||||
| 2025 | ||||
| $ | ||||
At December 31, 2021, the $
The
Company issued a
The Company issued a
11
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 5. | CONVERTIBLE PROMISSORY NOTES (Continued) |
The Company issued a
The Company issued a
On April 15, 2020, the Company issued
a convertible promissory note (the “Apr 2020 Note”) to an investor in the aggregate principal amount of $
All note conversions were performed per the terms of their respective
agreements.
12
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 6. | DERIVATIVE LIABILITIES |
ASC Topic 815 provides guidance applicable to convertible debt issued by the Company in instances where the number into which the debt can be converted is not fixed. For example, when a convertible debt converts at a discount to market based on the stock price on the date of conversion, ASC Topic 815 requires that the embedded conversion option of the convertible debt be bifurcated from the host contract and recorded at their fair value. In accounting for derivatives under accounting standards, the Company recorded a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the embedded derivative. The discount is amortized over the life of the convertible debt, and the derivative liability is adjusted periodically according to stock price fluctuations.
The convertible notes (the “Notes”) issued do not have fixed settlement provisions because their conversion prices are not fixed. The conversion features have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.
During the six months ended December
31, 2021, the Company recorded a net gain in change in derivative of $
At December 31,
2021, the fair value of the derivative liability was $
For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice formula. The significant assumptions used in the Binomial lattice formula of the derivatives are as follows:
| Risk free interest rate | ||
| Stock volatility factor | ||
| Weighted average expected option life | ||
| Expected dividend yield |
| 7. | MARKETABLE SECURITIES |
During the period ended December 31, 2021, the Company invested in corporate bonds, which have been recognized in the financial statements at fair value.
The Company considers corporate bonds (“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating between AAA and BBB.
As of December 31, 2021, the components of the Company’s short and long-term investments are summarized as follows:
| Short term investments: | ||||
| Bonds (held-to-maturity) | ||||
| Long term investments: | ||||
| Bonds (held-to-maturity) | ||||
| Total short and long-term investments | $ | |||
The Company has invested in bonds maturing from June 24, 2022 through April 15, 2025 that are held to maturity. The current trading prices or fair market value of the bonds vary, and we believe any decline in fair value is temporary. All bonds are current and not in default.
13
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 7. | MARKETABLE SECURITIES (Continued) |
The following table summarizes the amortized cost of the held-to-maturity bonds at December 31, 2021, aggregated by credit quality indicator.
| Credit Quality Indicators for the Corporate Bonds | ||||
| AA/A | $ | |||
| BBB | $ | |||
| Total | $ | |||
The amortized cost of our corporate bonds and the related gross unrealized gains and losses, were as follows at December 31, 2021:
| Gross Unrealized | ||||||||||||||||||
| Level | Cost | Gains | Losses | Fair Value | ||||||||||||||
| Bonds | 2 | ( | ) | $ | ||||||||||||||
During the period ended December 31,
2021, the Company recognized interest income of $
| 8. | COMMITMENTS AND CONTINGENCIES |
On September 15, 2020, the Company
entered into a marketing agreement. The fees are to be paid in cash and registered unrestricted stock. As of December 31, 2021, the Company
has paid a $
Effective
September 1, 2021,
Effective
October 1, 2021, the Company entered into a research agreement with the University of Michigan.
In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operation.
| 9. | RELATED PARTY |
As of June 30, 2021, the Company reported
an accrual associated with the CEO’s prior years’ salary in the amount of $
During the six months ended December
31, 2021, the Company redeemed
14
SUNHYDROGEN, INC.
CONDENSED NOTES TO FINANCIAL STATEMENTS – UNAUDITED
DECEMBER 31, 2021 AND 2020
| 10. | SUBSEQUENT EVENTS |
Management evaluated subsequent events as of the date of the financial statements pursuant to ASC TOPIC 855, and there were the following events to report.
On January 7, 2022, the Company issued
On January 27, 2022, the Company filed
a certificate of designation of Series A Preferred Stock with the Secretary of State of Nevada, and issued
Pursuant to the certificate of designation,
the Company designated
On January 27, 2022, the holder of
the majority of the voting power of the shareholders of the Company, and the Company’s chief executive officer, approved by written
consent (i) an amendment to the Company’s articles of incorporation to increase the Company’s authorized shares of common
stock from
15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Cautionary Statement Regarding Forward-Looking Statements
The information in this report may contain forward-looking statements. These forward-looking statements involve risks and uncertainties, including statements regarding our capital needs, business strategy and expectations. Any statements that are not of historical fact may be deemed to be forward-looking statements. These forward-looking statements involve substantial risks and uncertainties. In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue”, the negative of the terms or other comparable terminology. Actual events or results may differ materially from the anticipated results or other expectations expressed in the forward-looking statements. In evaluating these statements, you should consider various factors, including the risks included from time to time in our reports filed with the Securities and Exchange Commission, or the SEC. These factors may cause our actual results to differ materially from any forward-looking statements. We disclaim any obligation to publicly update these statements, or disclose any difference between actual results and those reflected in these statements, except as may be required under applicable law.
Unless the context otherwise requires, references in this Form 10-Q to “we,” “us,” “our,” or the “Company” refer to SunHydrogen, Inc.
Overview
At SunHydrogen, our goal is to replace fossil fuels with clean, renewable hydrogen.
Hydrogen is the most abundant chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct left behind is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that release carbon dioxide and other contaminants into the atmosphere when used. However, naturally occurring elemental hydrogen is rare. As a result, nearly all the world’s hydrogen is procured through steam methane reforming (SMR), a capital-intensive process that emits carbon dioxide and other harmful pollutants. Hydrogen is green, but currently the most common process for producing it is brown.
We believe the SunHydrogen solution potentially offers an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source of water. Our core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting in hydrogen. By optimizing the science of water electrolysis at the nano-level, we believe we have developed a low-cost method to potentially produce environmentally friendly renewable hydrogen. We believe renewable hydrogen is the fuel of the future, and we believe our technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.
We believe our solution is unique because it directly uses the electrical charges created by sunlight to generate hydrogen, eliminating the need for the power electronics that traditional electrolyzers rely on altogether. SunHydrogen’s expected scalable system configuration of many individual hydrogen-generating panels provides a high degree of redundancy, security and stability. And while electrolyzers require high-purity water for operation, SunHydrogen’s technology can utilize water of varying purities.
Additionally, because our process only requires sunlight and water, our technology can be installed near the point of hydrogen use. This eliminates the need for pipelines and trucks that result in high carbon emissions and high capital investment. With a target cost of $2.50/kg., we aspire for our technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen competitors. We believe our solution has the potential to clear a path for green hydrogen to compete with natural gas hydrogen and gain mass market acceptance as a true replacement for fossil fuels.
Our technology is primarily developed in Coralville, Iowa, where we have a sponsored research agreement with the University of Iowa as well as a dedicated laboratory space at the BioVentures Center at the University of Iowa Research Park. Our Iowa team has worked diligently over the past several years to lead and optimize the scale-up of our nanoparticle technology.
16
Outside of our internal team, we’ve made strides toward commercialization by forming relationships with industrial partners who possess specialized expertise in individual components of our technology.
In our partnership with SCHMID Group of Freudenstadt, Germany, they lead the engineering of our panel housing, a crucial system element that ensures safe and efficient hydrogen collection. We also have ongoing partnerships with InRedox of Longmont, Colorado and MSC Co. LTD of Korea which are focused on substrate manufacturing and electroplating chemistries, respectively. We also have a sponsored research agreement with the University of Michigan focused on catalyst optimization and membrane integration.
Most recently, we have entered into a new partnership with Geomatec, a high-performance thin film manufacturer based in Japan who will work alongside InRedox to facilitate our transition to large-scale substrate manufacturing.
We will continue working diligently with our existing partners, and engaging new partners, to drive our technology to commercialization. As we prepare for mass production, we will also continue seeking out potential manufacturing partners for production facility, equipment design and engineering.
Critical Accounting Policies
Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Binomial valuation option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.
Use of Estimates
In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2021, the amounts reported for cash, accrued interest and other expenses, notes payables, and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Recently Issued Accounting Pronouncements
Management reviewed currently issued pronouncements during the three months ended December 31, 2021, and does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. Pronouncements are disclosed in notes to the financial statements.
17
Results of Operations for the Three Months Ended December 31, 2021 compared to Three Months Ended December 31, 2020
Operating Expenses
Operating expenses for the three months ended December 31, 2021 were $737,611 compared to $2,731,648 for the three months ended December 31, 2020. The net decrease of $1,994,037 in operating expenses consisted primarily of a decrease in professional fees.
Other Income/(Expenses)
Other income and (expenses) for the three months ended December 31, 2021 were $25,169,373 compared to $(122,388,733) for the three months ended December 31, 2020. The decrease in other expenses of $147,558,106 was the result of a decrease in non-cash loss in net change in derivative of $147,432,554, a decrease in interest expense of $108,816, which includes the net change in amortization of debt discount of $85,599, with an increase in other income of $37,429, and an increase in loss on redemption of marketable securities of $20,693.
Net Income/(Loss)
For the three months ended December 31, 2021, our net income was $24,431,762, as compared to a net loss of $(125,120,381) for the three months ended December 31, 2020. The majority of the decrease in net loss of $149,552,143, was related primarily to the decrease in net change of derivative instruments estimated each period. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. The Company has not generated any revenues.
Results of Operations for the Six months ended December 31, 2021 compared to Six Months Ended December 31, 2020
Operating Expenses
Operating expenses for the six months ended December 31, 2021 were $1,337,377 compared to $3,310,134 for the six months ended December 31, 2020. The net decrease of $1,972,757 in operating expenses consisted primarily of a decrease in professional fees.
Other Income/(Expenses)
Other income and (expenses) for the six months ended December 31, 2021 were $74,393,983, compared to $(124,015,577) for the six months ended December 31, 2020. The decrease in other expenses of $198,409,560 was the result of a decrease in non-cash loss in net change in derivative of $198,164,764, a decrease in interest expense of $211,037, which includes the net change in amortization of debt discount of $181,249, and an increase in other income of $54,452, and an increase in loss on redemption of marketable securities of $20,693.
Net Income/(Loss)
For the six months ended December 31, 2021, our net income was $73,056,606, compared to a net loss of $(127,325,711) for the six months ended December 31, 2020. The majority of the decrease in net loss of $200,382,317, was related primarily to the decrease in net change of derivative instruments estimated each period. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. The Company has not generated any revenues.
18
Liquidity and Capital Resources
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.
As of December 31, 2021, we had a working capital deficit of $1,099,823, compared to a working capital deficit of $80,099,103 as of June 30, 2021. This decrease in working capital deficit of $78,999,280 was primarily due to the decrease in derivative liability and an increase in cash and cash equivalents.
Cash used in operating activities was $1,301,469, for the six months ended December 31, 2021, compared to $2,867,781 for the six months ended December 31, 2020. The decrease in cash used in operating activities was due to a decrease in professional fees. The Company has had no revenues.
Cash used in investing activities during the six months ended December 31, 2021 and 2020 was $8,653,932 and $53,961, respectively. The increase in investing activities was due to an increase in investment of markable securities.
Cash used in financing activities during the six months ended December 31, 2021 was $(1,450,000), compared to $20,092,300 provided by financing activities net of commission fees for the six months ended December 31, 2020. The decrease in cash provided in financing activities was due to a decrease in proceeds from the sale of common stock and warrants. Our ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placements and registered offerings of our securities, as we have not generated any revenues to date.
We have historically obtained funding from investors, through private placements and registered offerings of equity and debt securities. Management believes that the Company will be able to continue to raise funds through the sale of its securities to its existing shareholders and prospective new investors, which will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the Company to continue to develop its core business. There can be no assurance that we will be able to continue raising the required capital for our operations on terms and conditions that are acceptable to us, or at all. If we are unable to obtain sufficient funds, we may be forced to curtail and/or cease our operation.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, result of operations, liquidity or capital expenditures.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not required for smaller reporting companies.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change to our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
19
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently a party to, nor is any of our property currently the subject of, any material legal proceeding.
Item 1A. Risk Factors.
There are no material changes from the risk factors previously disclosed in our annual report on Form 10-K filed with the SEC on October 8, 2021.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
| Exhibit No. | Description | |
| 31.1* | Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302* | |
| 32.1** | Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350** | |
| 101* | Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q. | |
| 104* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |
| * | Filed herewith |
| ** | Furnished herewith |
20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| February 11, 2022 | SUNHYDROGEN, INC. | |
| By: | /s/ Timothy Young | |
|
Timothy Young Chief Executive Officer and (Principal Executive Officer, | ||
21
Exhibit 31.1
CERTIFICATION
PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Timothy Young, certify that:
1. I have reviewed this quarterly report on Form 10-Q of SunHydrogen, Inc. for the fiscal quarter ended December 31, 2021;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: February 11, 2022
| /s/ Timothy Young | |
| Timothy Young | |
|
Chief Executive Officer & Acting Chief Financial Officer (Principal Executive and Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of SunHydrogen, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2021 as filed with the Securities and Exchange Commission the date hereof (the “Report”), I, Timothy Young, Chief Executive Officer & Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: February 11, 2022 | /s/ Timothy Young |
| Timothy Young | |
| Chief Executive Officer & Acting Chief Financial Officer | |
| (Principal Executive and Financial Officer) |
Condensed Balance Sheets (Parentheticals) - USD ($) |
Dec. 31, 2021 |
Jun. 30, 2021 |
|---|---|---|
| Amortization of domain (in Dollars) | $ 4,754 | $ 4,223 |
| Amortization of trademark (in Dollars) | 543 | 371 |
| Amortization of patents (in Dollars) | 26,497 | 16,250 |
| Convertible promissory notes, net of debt discount for current liabilities (in Dollars) | 215,573 | 409,074 |
| Convertible promissory notes, net of debt discount for long term liabilities (in Dollars) | $ 0 | $ 0 |
| Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 |
| Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
| Common stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 5,000,000,000 | 5,000,000,000 |
| Common stock, shares issued | 4,029,789,187 | 3,849,308,495 |
| Common stock, shares outstanding | 4,029,789,187 | 3,849,308,495 |
| Series C preferred shares | ||
| Preferred stock, shares issued | 2,700 | 2,700 |
| Preferred stock, shares outstanding | 2,700 | 2,700 |
Condensed Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Income Statement [Abstract] | ||||
| REVENUE | ||||
| OPERATING EXPENSES | ||||
| Selling and Marketing | 87,590 | 197,366 | ||
| General and administrative expenses | 353,885 | 2,286,980 | 680,470 | 2,725,170 |
| Research and development cost | 285,853 | 439,987 | 437,215 | 578,247 |
| Depreciation and amortization | 10,283 | 4,681 | 22,326 | 6,717 |
| TOTAL OPERATING EXPENSES | 737,611 | 2,731,648 | 1,337,377 | 3,310,134 |
| LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) | (737,611) | (2,731,648) | (1,337,377) | (3,310,134) |
| OTHER INCOME/(EXPENSES) | ||||
| Other income | 37,877 | 448 | 54,900 | 448 |
| Loss on redemption of marketable securities | (20,693) | (20,693) | ||
| Loss on settlement of derivative liability | (841,596) | (841,596) | ||
| Gain (Loss) on change in derivative liability | 26,135,397 | (122,138,753) | 75,487,522 | (123,518,838) |
| Interest expense | (141,612) | (250,428) | (286,150) | (497,187) |
| TOTAL OTHER INCOME (EXPENSES) | 25,169,373 | (122,388,733) | 74,393,983 | (124,015,577) |
| NET INCOME (LOSS) | 24,431,762 | (125,120,381) | 73,056,606 | (127,325,711) |
| COMMON STOCK WARRANTS DEEMED DIVIDENDS | (15,928,314) | (15,928,314) | ||
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ 24,431,762 | $ (141,048,695) | $ 73,056,606 | $ (143,254,025) |
| BASIC EARNINGS (LOSS) PER SHARE (in Dollars per share) | $ 0.01 | $ (0.05) | $ 0.02 | $ (0.06) |
| DILUTED EARNINGS (LOSS) PER SHARE (in Dollars per share) | $ 0 | $ (0.05) | $ 0.01 | $ (0.06) |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING | ||||
| BASIC (in Shares) | 4,029,789,187 | 2,317,322,842 | 4,015,076,087 | 2,228,251,336 |
| DILUTED (in Shares) | 5,304,670,650 | 2,317,322,842 | 5,289,957,550 | 2,228,251,336 |
Basis of Presentation |
6 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 | |||
| Accounting Policies [Abstract] | |||
| Basis of Presentation |
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ended June 30, 2022. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended June 30, 2021. |
Summary of Significant Accounting Policies |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
This summary of significant accounting policies of SunHydrogen, Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.
Cash and Cash Equivalent
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Marketable Securities
The Company considers corporate bonds (“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating of AAA and BBB.
The bonds have varied due dates and were classified as current and noncurrent, based on to their maturity dates. The bonds are generally valued using quoted prices and are classified in Level 2 of the fair value hierarchy as prices are not always from active markets. We consider our investments held to maturity and we believe there are no other than temporary declines in fair value. Our investments are recorded at historical cost.
Use of Estimates
In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
Property and Equipment
Property and equipment are stated at cost and are depreciated using straight line over its estimated useful lives.
The Company recognized depreciation expense of $18,809 and $3,200 for the six months ended December 31, 2021 and 2020, respectively.
Intangible Assets
The Company has patent applications to protect the inventions and processes behind its proprietary solar-to-hydrogen based technology. Intangible assets that have finite useful lives continue to be amortized over their useful lives.
The Company recognized amortization expense of $3,517 and $3,517 for the six months ended December 31, 2021 and 2020, respectively.
Net Earnings (Loss) per Share Calculations
Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).
December 31, 2021
For the six months ended December 31, 2021, the Company calculated the dilutive impact of the outstanding stock options of 157,965,711, common stock purchase warrants of 94,895,239, and convertible debt of $963,000 and interest of $210,384, which is convertible into shares of common stock. The stock options were not included in the earnings per share, because their impact was antidilutive, and the warrants and convertible debt were included in earnings per share, because their impact was dilutive.
December 31, 2020
For the six months ended December 31, 2020, the Company calculated the dilutive impact of the outstanding stock options of 196,000,000, common stock purchase warrants of 148,800,000, and convertible debt of $1,361,200 and interest of $433,436, which is convertible into shares of common stock. The stock options, warrants, and convertible debt were not included in the calculation of net earnings per share, because their impact was antidilutive.
Equity Incentive Plan and Stock Options
Equity Incentive Plan
On December 17, 2018, the Board of Directors approved and adopted the 2019 Equity Incentive Plan (“the Plan”), with 300,000,000 shares reserved for issuance pursuant to the Plan. The purpose of the Plan is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The awards are performance-based compensation that are granted under the Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option. The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing cost. The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date. The options are exercisable into common stock.
Stock Based Compensation
The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.
Warrant Accounting
The Company accounts for the warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.
Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2021, the amounts reported for cash, accrued interest and other expenses, notes payables, convertible notes, and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:
We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows on December 31, 2021 (See Note 6):
The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:
Research and Development
Research and development costs are expensed as incurred. Total research and development costs were $437,215 and $578,247 for the six months ended December 31, 2021 and 2020, respectively.
Accounting for Derivatives
The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Recently Issued Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements as of December 31, 2021. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock |
6 Months Ended | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||||
| Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||||
| CAPITAL STOCK |
Preferred Stock
On December 15, 2021, the Company filed a certificate of designation of preferences, right and limitations of Series C Preferred Stock with the Secretary of State of Nevada, designating 17,000 shares of preferred stock, par value $0.001 of the Company, as Series C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $100 and is convertible into shares of common stock of the Company at a conversion price equal to $0.00095.
The Company entered into a securities purchase agreement on December 15, 2021, with an accredited investor for an exchange of convertible debt to equity. The investor exchanged a convertible note in the amount of $187,800, plus accrued interest of $80,365 for an aggregate total of $268,165 for 2,700 shares of the Company’s Series C Preferred Stock. The extinguishment of the convertible debt was recognized in the Company’s financials as a loss on settlement of derivative liability. A valuation was prepared using the Monte Carlo Method, based on a stock price of $0.0469, with a volatility of 131.5% and risk-free rate of 0.84% based on an estimated term of five (5) years. The note was tendered to the Company for cancellation and foregoes all future accrued interest.
The Company recognized a loss on settlement of $841,596 for the extinguishment of convertible debt, plus derivative liability for the period ended December 31, 2021.
Common Stock
Six months ended December 31, 2021
During the six months ended December 31, 2021, the Company issued 180,480,692 shares of common stock upon conversion of convertible notes in the amount of $120,400 of principal, plus accrued interest of $51,057 based upon a conversion price of $0.00095 per share. The notes were converted per the terms of their respective agreements and therefore no gain or loss on the conversion was recorded.
Six months ended December 31, 2020
During the six months ended December 31, 2020, the Company issued 219,210,319 shares of common stock for cash at prices ranging from $0.022 - $0.025 for aggregate net proceeds of $2,2092,300 plus offering cost of $107,700 for a total of $2,200,000; and issued an additional 120,000,000 shares of common stock under a securities purchase agreement, whereby the funds were split between the fair value of the securities purchase agreement in the amount of $5,099,933 and the warrants issued with the securities purchase agreement in the amount of $3,900,067 for a total price of $9,000,000.
During the six months ended December 31, 2020, the Company issued 120,000,000 shares of common stock upon exercise of warrants at an exercise price of $0.075 for gross proceeds of $9,000,000.
During the six months ended December 31, 2020, the Company issued 275,532,747 shares of common stock upon conversion of convertible notes in the amount of $668,800 of principal, plus accrued interest of $87,716 and other fees of $1,800 based upon conversion prices ranging from $0.00095 - $0.017995 per share. All note conversions were performed per the terms of their respective agreements and therefore no gain or loss on the conversion was recorded.
During the six months ended December 31, 2020, the Company issued 3,806,290 shares of common stock for services rendered at fair value prices of $0.028 - $0.035 per share in the aggregate amount of $118,023. |
||||||||||||||||||||||||||||||||
Options and Warrants |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OPTIONS AND WARRANTS |
OPTIONS
As of September 30, 2020, 10,000,000 non-qualified common stock options were outstanding. Each option expires on the date specified in the option agreement, which date is not later than the fifth (5th) anniversary from the grant date of the options. Of the 10,000,000 non-qualified common stock options, one-third vest immediately, and one-third vest the second and third year, such that the options are fully vested with a maturity date of October 2, 2022 and are exercisable at an exercise price of $0.01 per share.
On January 23, 2019, the Company issued 170,000,000 stock options. One-third of the options vested immediately, and the remainder vest 1/24 per month over the first twenty-four months following the option grant. The options expire 10 years from the initial grant date. The options fully vest by January 23, 2022
On January 31, 2019, the Company issued 6,000,000 stock options, of which two-third (2/3) vest immediately, and the remaining amount shall vest one-twelfth (1/12) per month from after the date of the option grant. The options expire 10 years from the initial grant date. The options fully vested on January 31, 2020.
On July 22, 2019, the Company issued 10,000,000 stock options, of which one-third (1/3) vest immediately, and the remaining shall vest one-twenty fourth (1/24) per month from after the date of the option grant. The options expire 10 years from the initial grant date. The options fully vested on July 22, 2020.
A summary of the Company’s stock option activity and related information follows:
During the six months ended December 31, 2021, the Company bought back a total of 24,887,463 of the Company’s stock options for a total of $1,450,000. The options were bought back for the market price at the date of the buy-back less the exercise price of the grant. All options that were bought back were fully vested and previously expensed accordingly.
The weighted average remaining contractual life of options outstanding as of December 31, 2021 and 2020 was as follows:
The stock-based compensation expense recognized in the statement of operations during the six months ended December 31, 2021 and 2020, related to the granting of these options was $0 and $224,070, respectively.
WARRANTS
As of December 31, 2021, the Company had an aggregate of 94,895,239 common stock purchase warrants outstanding, with exercise prices ranging from $0.0938 - $0.13125 per share. The warrants were estimated at fair value on the date of issuance as calculated using the Black-Scholes valuation model. The warrants can be exercised over periods of three (3) to five (5) years.
A summary of the Company’s warrant activity and related information follows for the six months ended December 31, 2021.
At December 31, 2021, the aggregate intrinsic value of the warrants outstanding was $0. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||
| CONVERTIBLE PROMISSORY NOTES |
As of December 31, 2021, the outstanding convertible promissory notes net of debt discount are summarized as follows:
Maturities of long-term debt for the next five years are as follows:
At December 31, 2021, the $963,000 in convertible promissory notes had a remaining debt discount of $215,753, leaving a net balance of $747,247.
The Company issued a 10% convertible promissory note on February 3, 2017 (the “Feb 2017 Note”) in the aggregate principal amount of up to $500,000. The Company received tranches for an aggregate principal total of $500,000. The Feb 2017 Note had a maturity date of February 3, 2018, which the investor extended the Feb 2017 Note for an additional sixty (60) months from the effective date of the note, to February 3, 2022. The Feb 2017 Note was convertible into shares of common stock of the Company at a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price since the original effective date of the note or the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Company failed to deliver shares in accordance with the timeframe of three (3) business days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, could rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded conversion shares returned to the Company. In no event was the lender be entitled to convert any portion of the Feb 2017 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion, in the event, that shares were not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day would be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. During the period ended on December 31, 2021, the Company issued 180,480,692 shares of common stock upon conversion of principal in the amount of $120,400, plus accrued interest of $51,057. Also, during the six months ended December 31, 2021, the Company exchanged the balance of the convertible note in the amount of $187,800, plus accrued interest of $80,365 for an aggregate total of $268,165, for 2,700 Series C preferred shares with a stated value of $100 per share and a 10% annual dividend. The preferred shares are convertible into common stock at a fixed conversion price of $0.00095. The balance of the Feb 2017 Note as of December 31, 2021 was $0.
The Company issued a 10% convertible promissory note on November 9, 2017 (the “Nov 2017 Note”) in the aggregate principal amount of up to $500,000. The Company received tranches for an aggregate principal total of 500,000. The Nov 2017 Note had a maturity date of November 9, 2018, with an automatic extension of sixty (60) months from the effective date of the note. The Nov 2017 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price since the original effective date of the note or the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Company fails to deliver shares in accordance with the timeframe of three (3) business days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded conversion shares returned to the Company. In no event shall the lender be entitled to convert any portion of the Nov 2017 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The balance of the Nov 2017 Note as of December 31, 2021 was $313,000.
The Company issued a 10% convertible promissory note on June 27, 2018 (the “Jun 2018 Note”) in the aggregate principal amount of up to $500,000. The Company received tranches for an aggregate principal total of $500,000. The Jun 2018 Note matured on June 27, 2019, which was automatically extended for sixty (60) months from the effective date of the note. The Jun 2018 Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price since the original effective date of the note or the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Company fails to deliver shares in accordance with the timeframe of three (3) business days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded conversion shares returned to the Company. In no event shall the lender be entitled to convert any portion of the Jun 2018 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion, in the event, that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $206,685 during the six months ended December 31, 2021.The balance of the Jun 2018 Note as of December 31, 2021 was $500,000.
The Company issued a 10% convertible promissory note on August 10, 2018 (the “Aug 2018 Note”) in the aggregate principal amount of up to $100,000. The Aug 2018 Note had a maturity date of August 10, 2019, with an extension of sixty (60) months from the date of the note. The Aug 2018 Note matures on August 10, 2023. The Aug 2018 Note may be converted into shares of the Company’s common stock at a conversion price of the lesser of a) $0.005 per share or b) sixty-one (61%) percent of the lowest trading price per common stock recorded on any trade day after the effective date. The conversion feature of the Aug 2018 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Note. The balance of the Aug 2018 Note as of December 31, 2021 was $100,000.
On April 15, 2020, the Company issued a convertible promissory note (the “Apr 2020 Note”) to an investor in the aggregate principal amount of $50,000. The Company received tranches for an aggregate principal total of $50,000. The Apr 2020 Note matures twelve (12) months from the effective dates of each respective tranche, such that the Apr 2020 Note matures on April 15, 2021, with an automatic extension of sixty (60) months from the effective date of each tranche. The Apr Note is convertible into shares of common stock of the Company at a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price of the common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Company fails to deliver shares in accordance with the timeframe of four (4) business days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded conversion shares returned to the Company. In no event shall the lender be entitled to convert any portion of the Apr 2020 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $2,000 per day shall be assessed for each day after the fourth business day (inclusive of the day of the conversion) until the shares are delivered. The conversion feature of the April 2020 Note was considered a derivative in accordance with current accounting guidelines because of the reset conversion features of the Apr 2020 Note. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $20,164 during the six months ended December 31, 2021. The balance of the Apr 2020 Note as of December 31, 2021 was $50,000.
All note conversions were performed per the terms of their respective agreements. At December 31, 2021, the Company recognized a loss of $841,596 on conversion of a convertible note in exchange for Series C preferred stock. |
|||||||||||||||||||||||||||||||||||||||||||||||
Derivative Liabilities |
6 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||
| DERIVATIVE LIABILITIES |
ASC Topic 815 provides guidance applicable to convertible debt issued by the Company in instances where the number into which the debt can be converted is not fixed. For example, when a convertible debt converts at a discount to market based on the stock price on the date of conversion, ASC Topic 815 requires that the embedded conversion option of the convertible debt be bifurcated from the host contract and recorded at their fair value. In accounting for derivatives under accounting standards, the Company recorded a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the embedded derivative. The discount is amortized over the life of the convertible debt, and the derivative liability is adjusted periodically according to stock price fluctuations.
The convertible notes (the “Notes”) issued do not have fixed settlement provisions because their conversion prices are not fixed. The conversion features have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.
During the six months ended December 31, 2021, the Company recorded a net gain in change in derivative of $75,487,522 in the statement of operations due to the change in fair value of the remaining notes, for the six months ended December 31, 2021.
At December 31, 2021, the fair value of the derivative liability was $46,528,773.
For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice formula. The significant assumptions used in the Binomial lattice formula of the derivatives are as follows:
|
Marketable Securities |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MARKETABLE SECURITIES |
During the period ended December 31, 2021, the Company invested in corporate bonds, which have been recognized in the financial statements at fair value.
The Company considers corporate bonds (“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating between AAA and BBB.
As of December 31, 2021, the components of the Company’s short and long-term investments are summarized as follows:
The Company has invested in bonds maturing from June 24, 2022 through April 15, 2025 that are held to maturity. The current trading prices or fair market value of the bonds vary, and we believe any decline in fair value is temporary. All bonds are current and not in default.
The following table summarizes the amortized cost of the held-to-maturity bonds at December 31, 2021, aggregated by credit quality indicator.
The amortized cost of our corporate bonds and the related gross unrealized gains and losses, were as follows at December 31, 2021:
During the period ended December 31, 2021, the Company recognized interest income of $46,980 in the financial statements. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies |
6 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 | |||
| Commitments and Contingencies Disclosure [Abstract] | |||
| COMMITMENTS AND CONTINGENCIES |
On September 15, 2020, the Company entered into a marketing agreement. The fees are to be paid in cash and registered unrestricted stock. As of December 31, 2021, the Company has paid a $34,250 deposit, with the balance of the payments and the stock issuances due upon completion of a deliverable.
Effective September 1, 2021, the Company entered into a new research agreement with the University of Iowa. As consideration under the research agreement, the University of Iowa will receive a maximum of $350,000 from the Company. The contract period is from September 1, 2021 through August 31, 2022. The research agreement may be terminated by either party upon sixty (60) day prior written notice or a material breach or default, which is not cured within 90 days of receipt of a written notice of such breach. This agreement was signed by the Company on September 13, 2021. As of December 31, 2021, the Company has accrued the amount due of $116,666.
Effective October 1, 2021, the Company entered into a research agreement with the University of Michigan. As consideration under the research agreement, the University of Michigan will receive a maximum of $296,448, from the Company. The research agreement may be terminated by either party upon ninety (90) day prior written notice or a material breach or default, which is not cured within 90 days of receipt of a written notice of such breach. This agreement was signed by the Company on September 23, 2021.
In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operation. |
Related Party |
6 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 | |||
| Related Party Transactions [Abstract] | |||
| RELATED PARTY |
As of June 30, 2021, the Company reported an accrual associated with the CEO’s prior years’ salary in the amount of $211,750, plus current accrual of $14,750 for a total of $226,500, which is recorded in related party accrued expenses. The Company began accruing the salary in 2011 and used the funds for operating expenses. The CEO will be paid during the fiscal year.
During the six months ended December 31, 2021, the Company redeemed 24,887,463 shares of the Company’s stock options to related parties for a total of $1,450,000. |
Subsequent Events |
6 Months Ended | ||
|---|---|---|---|
Dec. 31, 2021 | |||
| Subsequent Events [Abstract] | |||
| SUBSEQUENT EVENTS |
Management evaluated subsequent events as of the date of the financial statements pursuant to ASC TOPIC 855, and there were the following events to report.
On January 7, 2022, the Company issued 200,976,352 shares of common stock upon conversion of principal in the amount of $135,500, plus accrued interest of $55,428 associated with the November 9, 2017 convertible note.
On January 27, 2022, the Company filed a certificate of designation of Series A Preferred Stock with the Secretary of State of Nevada, and issued 1,000 shares of Series A Preferred Stock to the Company’s chief executive officer, for services rendered.
Pursuant to the certificate of designation, the Company designated 1,000 shares of preferred stock as Series A Preferred Stock. The Series A Preferred Stock is not convertible into common stock, and does not have any dividend rights or any liquidation preference. The Series A Preferred Stock entitles the holder to 51% of the voting power of the Company’s stockholders. The Series A Preferred Stock will automatically be redeemed by the Company at the par value of $0.001 per share, on the first to occur of the following events: (i) a date sixty days after the effective date of the certificate of designation, (ii) the date that Timothy Young ceases to serve as officer, director or consultant of the Company, or (iii) on the date that the Company’s shares of common stock first trade on any national securities exchange and such listing is conditioned upon the elimination of the preferential voting rights.
On January 27, 2022, the holder of the majority of the voting power of the shareholders of the Company, and the Company’s chief executive officer, approved by written consent (i) an amendment to the Company’s articles of incorporation to increase the Company’s authorized shares of common stock from 5,000,000,000 to 10,000,000,000, (ii) an amendment to the Company’s articles of incorporation to effect a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-100 and not more than 1-for-500 at any time prior to the one year anniversary of filing the definitive information statement with respect to the reverse split, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number within the above range as determined by the board in its discretion, and (iii) the adoption of the Company’s 2022 Equity Incentive Plan. Such shareholder approval for such actions will be effective 20 days after the definitive information statement relating to such actions is mailed to shareholders. |
Accounting Policies, by Policy (Policies) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash and Cash Equivalent | Cash and Cash Equivalent
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Marketable Securities | Marketable Securities
The Company considers corporate bonds (“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating of AAA and BBB.
The bonds have varied due dates and were classified as current and noncurrent, based on to their maturity dates. The bonds are generally valued using quoted prices and are classified in Level 2 of the fair value hierarchy as prices are not always from active markets. We consider our investments held to maturity and we believe there are no other than temporary declines in fair value. Our investments are recorded at historical cost.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates | Use of Estimates
In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property and Equipment | Property and Equipment
Property and equipment are stated at cost and are depreciated using straight line over its estimated useful lives.
The Company recognized depreciation expense of $18,809 and $3,200 for the six months ended December 31, 2021 and 2020, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets | Intangible Assets
The Company has patent applications to protect the inventions and processes behind its proprietary solar-to-hydrogen based technology. Intangible assets that have finite useful lives continue to be amortized over their useful lives.
The Company recognized amortization expense of $3,517 and $3,517 for the six months ended December 31, 2021 and 2020, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Earnings (Loss) per Share Calculations | Net Earnings (Loss) per Share Calculations
Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock-based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).
December 31, 2021
For the six months ended December 31, 2021, the Company calculated the dilutive impact of the outstanding stock options of 157,965,711, common stock purchase warrants of 94,895,239, and convertible debt of $963,000 and interest of $210,384, which is convertible into shares of common stock. The stock options were not included in the earnings per share, because their impact was antidilutive, and the warrants and convertible debt were included in earnings per share, because their impact was dilutive.
December 31, 2020
For the six months ended December 31, 2020, the Company calculated the dilutive impact of the outstanding stock options of 196,000,000, common stock purchase warrants of 148,800,000, and convertible debt of $1,361,200 and interest of $433,436, which is convertible into shares of common stock. The stock options, warrants, and convertible debt were not included in the calculation of net earnings per share, because their impact was antidilutive.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Incentive Plan and Stock Options | Equity Incentive Plan and Stock Options
Equity Incentive Plan
On December 17, 2018, the Board of Directors approved and adopted the 2019 Equity Incentive Plan (“the Plan”), with 300,000,000 shares reserved for issuance pursuant to the Plan. The purpose of the Plan is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The awards are performance-based compensation that are granted under the Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option. The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing cost. The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date. The options are exercisable into common stock.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock Based Compensation | Stock Based Compensation
The Company accounts for stock option grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Warrant Accounting | Warrant Accounting
The Company accounts for the warrants to purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value of Financial Instruments | Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December 31, 2021, the amounts reported for cash, accrued interest and other expenses, notes payables, convertible notes, and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:
We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows on December 31, 2021 (See Note 6):
The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and Development | Research and Development
Research and development costs are expensed as incurred. Total research and development costs were $437,215 and $578,247 for the six months ended December 31, 2021 and 2020, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting for Derivatives | Accounting for Derivatives
The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at inception and on subsequent valuation dates.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements
Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements as of December 31, 2021. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of property and equipment estimated useful lives |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of measurement of assets and liabilities at fair value on recurring basis |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of reconciliation of the derivative liability |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||
| Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||
| Schedule of capital stock |
|
||||||||||||||||||||||||||||||
Options and Warrants (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of the company's stock option activity and related information |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of weighted average remaining contractual life of options outstanding |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of company’s warrant activity and related information |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of aggregate intrinsic value of the warrants outstanding |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||
| Schedule of convertible promissory notes |
|
||||||||||||||||||||||||||||||
| Schedule of maturities of long-term debt |
|
||||||||||||||||||||||||||||||
Derivative Liabilities (Tables) |
6 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||
| Schedule of fair market value of the derivative liability |
|
Marketable Securities (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of cash and short and long-term investments |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of amortized cost of the held-to-maturity bonds |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of gross unrealized gains and losses |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies (Details) - USD ($) |
1 Months Ended | 6 Months Ended | |
|---|---|---|---|
Dec. 17, 2018 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Summary of Significant Accounting Policies (Details) [Line Items] | |||
| Amortization expense | $ 18,809 | $ 3,200 | |
| Depreciation expense | 3,517 | 3,517 | |
| Outstanding stock amount | $ 157,965,711 | $ 196,000,000 | |
| Warrants outstanding (in Shares) | 94,895,239 | 148,800,000 | |
| Convertible debt | $ 963,000 | $ 1,361,200 | |
| Interest | 210,384 | 433,436 | |
| Percentage of exercise option | 100.00% | ||
| Research and development | $ 437,215 | $ 578,247 | |
| Equity Incentive Plan [Member] | |||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||
| Issuance pursuant to the Plan (in Shares) | 300,000,000 | ||
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives |
6 Months Ended |
|---|---|
Dec. 31, 2021 | |
| Computers and Peripheral Equipment [Member] | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 5 years |
| Vehicle [Member] | |
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives | 5 years |
Summary of Significant Accounting Policies (Details) - Schedule of measurement of assets and liabilities at fair value on recurring basis - Fair value on a Recurring Basis [Member] |
Dec. 31, 2021
USD ($)
|
|---|---|
| Assets: | |
| Marketable securities measured at fair value | $ 8,480,269 |
| Liabilities: | |
| Derivative liabilities measured at fair value | 46,528,773 |
| Level 1 [Member] | |
| Assets: | |
| Marketable securities measured at fair value | |
| Liabilities: | |
| Derivative liabilities measured at fair value | |
| Level 2 [Member] | |
| Assets: | |
| Marketable securities measured at fair value | 8,480,269 |
| Liabilities: | |
| Derivative liabilities measured at fair value | |
| Level 3 [Member] | |
| Assets: | |
| Marketable securities measured at fair value | |
| Liabilities: | |
| Derivative liabilities measured at fair value | $ 46,528,773 |
Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the derivative liability - Fair Value, Inputs, Level 3 [Member] |
6 Months Ended |
|---|---|
|
Dec. 31, 2021
USD ($)
| |
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
| Beginning balance | $ 135,247,303 |
| Fair value of derivative liability removed | (13,231,008) |
| Gain on change in derivative liability | (75,487,522) |
| Ending balance | $ 46,528,773 |
Capital Stock (Details) - Schedule of capital stock |
Dec. 31, 2021
USD ($)
shares
|
|---|---|
| Per Valuation | |
| Preferred shares issued (in Shares) | shares | 2,700 |
| Stated value of debt and interest | $ 268,165 |
| Calculated fair value of preferred shares | 14,340,769 |
| Fair value of derivative liability removed | 13,231,008 |
| Loss on settlement | $ 841,596 |
Options and Warrants (Details) - USD ($) |
1 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2020 |
Jul. 22, 2019 |
Jan. 31, 2019 |
Jan. 23, 2019 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Options and Warrants (Details) [Line Items] | ||||||
| Stock options granted | ||||||
| Stock option, description | the Company issued 10,000,000 stock options, of which one-third (1/3) vest immediately, and the remaining shall vest one-twenty fourth (1/24) per month from after the date of the option grant. The options expire 10 years from the initial grant date. The options fully vested on July 22, 2020. | the Company issued 6,000,000 stock options, of which two-third (2/3) vest immediately, and the remaining amount shall vest one-twelfth (1/12) per month from after the date of the option grant. The options expire 10 years from the initial grant date. The options fully vested on January 31, 2020 | ||||
| Bought back shares | 24,887,463 | |||||
| Stock option total | $ 1,450,000 | |||||
| Stock compensation expense | 0 | $ 224,070 | ||||
| Warrants outstanding | $ 0 | |||||
| Warrants purchased for a period | 3 years | 5 years | ||||
| Warrant [Member] | ||||||
| Options and Warrants (Details) [Line Items] | ||||||
| Stock options granted | ||||||
| Stock warrants purchased | 94,895,239 | |||||
| Warrant [Member] | Minimum [Member] | ||||||
| Options and Warrants (Details) [Line Items] | ||||||
| Warrant exercise price | $ 0.0938 | |||||
| Warrant [Member] | Maximum [Member] | ||||||
| Options and Warrants (Details) [Line Items] | ||||||
| Warrant exercise price | $ 0.13125 | |||||
| Stock Option Plan [Member] | ||||||
| Options and Warrants (Details) [Line Items] | ||||||
| Stock options granted | 10,000,000 | 170,000,000 | ||||
| Stock option, description | One-third of the options vested immediately, and the remainder vest 1/24 per month over the first twenty-four months following the option grant. The options expire 10 years from the initial grant date. The options fully vest by January 23, 2022On January 31, 2019, the Company issued 6,000,000 stock options, of which two-third (2/3) vest immediately, and the remaining amount shall vest one-twelfth (1/12) per month from after the date of the option grant. The options expire 10 years from the initial grant date. The options fully vested on January 31, 2020. On July 22, 2019, the Company issued 10,000,000 stock options, of which one-third (1/3) vest immediately, and the remaining shall vest one-twenty fourth (1/24) per month from after the date of the option grant. The options expire 10 years from the initial grant date. | Of the 10,000,000 non-qualified common stock options, one-third vest immediately, and one-third vest the second and third year, such that the options are fully vested with a maturity date of October 2, 2022 and are exercisable at an exercise price of $0.01 per share. | ||||
Options and Warrants (Details) - Schedule of the company's stock option activity and related information - $ / shares |
6 Months Ended | |
|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Schedule of the company's stock option activity and related information [Abstract] | ||
| Number of Options outstanding, beginning of period | 182,853,174 | 196,250,000 |
| Weighted average exercise price, beginning of period | $ 0.01 | $ 0.01 |
| Number of Options Granted | ||
| Weighted average exercise price Granted | $ 0.01 | |
| Number of Options Exercised | ||
| Weighted average exercise price Exercised | ||
| Number of Options Buyback of options | (24,887,463) | (250,000) |
| Weighted average exercise price Buyback of options | $ 0.0099 | $ 0.01 |
| Number of Options Outstanding, end of period | 157,965,711 | 196,000,000 |
| Weighted average exercise price Outstanding, end of period | $ 0.0089 | $ 0.01 |
| Number of Options Exercisable at the end of period | 157,965,711 | 189,332,999 |
| Weighted average exercise price Exercisable at the end of period | $ 0.0089 | $ 0.01 |
Convertible Promissory Notes (Details) - USD ($) |
1 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Aug. 10, 2018 |
Nov. 09, 2017 |
Feb. 03, 2017 |
Jun. 27, 2018 |
Dec. 31, 2021 |
Dec. 15, 2021 |
Sep. 30, 2021 |
Dec. 31, 2020 |
Apr. 15, 2020 |
|
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Convertible promissory notes | $ 963,000 | $ 1,361,200 | |||||||
| Aggregate principal amount | $ 500,000 | $ 187,800 | $ 50,000 | ||||||
| Conversion of principal amount (in Shares) | 120,400 | ||||||||
| Accrued interest | $ 51,057 | ||||||||
| Fixed conversion price (in Dollars per share) | $ 0.00095 | ||||||||
| Convertible promissory note percentage | 10.00% | ||||||||
| Aggregate principal total | $ 500,000 | ||||||||
| Recognized interest expense amount | $ 206,685 | ||||||||
| Convertible note, description | At December 31, 2021, the Company recognized a loss of $841,596 on conversion of a convertible note in exchange for Series C preferred stock. | ||||||||
| Convertible promissory notes [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Convertible promissory notes | $ 963,000 | ||||||||
| Debt discount | 215,753 | ||||||||
| Net balance of convertible debt | 747,247 | ||||||||
| Feb 2017 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Aggregate principal amount | $ 0 | ||||||||
| Nov 2017 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Aggregate principal amount | 313,000 | ||||||||
| Aggregate principal amount | $ 500,000 | ||||||||
| Percentage of beneficial ownership | 4.99% | ||||||||
| Penalty amount | $ 1,500 | ||||||||
| Jun 2018 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Aggregate principal amount | 500,000 | ||||||||
| Aug 2018 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Convertible notes, interest rate | 10.00% | ||||||||
| Aggregate principal amount | $ 100,000 | 100,000 | |||||||
| Debt instrument, maturity date description | The Aug 2018 Note may be converted into shares of the Company’s common stock at a conversion price of the lesser of a) $0.005 per share or b) sixty-one (61%) percent of the lowest trading price per common stock recorded on any trade day after the effective date. | ||||||||
| Aug 2018 Note [Member] | 10% Unsecured Convertible Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Debt instrument, maturity date description | The Aug 2018 Note had a maturity date of August 10, 2019, with an extension of sixty (60) months from the date of the note. The Aug 2018 Note matures on August 10, 2023. | ||||||||
| April 2020 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Aggregate principal amount | $ 50,000 | ||||||||
| Percentage of beneficial ownership | 4.99% | ||||||||
| Penalty amount | $ 2,000 | ||||||||
| Conversion price (in Dollars per share) | $ 0.01 | ||||||||
| Interest expense amount | 20,164 | ||||||||
| Convertible notes payable | $ 50,000 | ||||||||
| 10% Convertible Promissory Note [Member] | Feb 2017 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Convertible notes, interest rate | 10.00% | ||||||||
| Aggregate principal amount | $ 500,000 | ||||||||
| Debt instrument, maturity date description | The Feb 2017 Note was convertible into shares of common stock of the Company at a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price since the original effective date of the note or the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Company failed to deliver shares in accordance with the timeframe of three (3) business days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, could rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded conversion shares returned to the Company. In no event was the lender be entitled to convert any portion of the Feb 2017 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion, in the event, that shares were not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day would be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. | ||||||||
| 10% Convertible Promissory Note [Member] | Feb 2017 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Aggregate principal amount | $ 500,000 | ||||||||
| Debt instrument, maturity date description | The Feb 2017 Note had a maturity date of February 3, 2018, which the investor extended the Feb 2017 Note for an additional sixty (60) months from the effective date of the note, to February 3, 2022. | ||||||||
| 10% Convertible Promissory Note [Member] | Jun 2018 Note [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Convertible notes, interest rate | 10.00% | ||||||||
| Aggregate principal amount | $ 500,000 | ||||||||
| Debt instrument, maturity date description | The Jun 2018 Note matured on June 27, 2019, which was automatically extended for sixty (60) months from the effective date of the note. | ||||||||
| Common Stock [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Common stock shares Issued (in Shares) | 180,480,692 | ||||||||
| Series C preferred shares [Member] | |||||||||
| Convertible Promissory Notes (Details) [Line Items] | |||||||||
| Conversion of principal amount (in Shares) | 187,800 | ||||||||
| Accrued interest | $ 80,365 | ||||||||
| Aggregate total | $ 268,165 | ||||||||
| Series C preferred shares (in Shares) | 2,700 | ||||||||
| Preferred stock, par value (in Dollars per share) | $ 100 | ||||||||
| Percentage of annual dividend | 10.00% |
Convertible Promissory Notes (Details) - Schedule of convertible promissory notes |
Dec. 31, 2021
USD ($)
|
|---|---|
| Debt Disclosure [Abstract] | |
| Convertible Promissory Notes, net of debt discount | $ 747,247 |
| Less current portion | 339,247 |
| Total long-term liabilities | $ 408,000 |
Convertible Promissory Notes (Details) - Schedule of maturities of long-term debt |
Dec. 31, 2021
USD ($)
|
|---|---|
| Debt Disclosure [Abstract] | |
| 2022 | $ 555,000 |
| 2023 | 398,000 |
| 2024 | |
| 2025 | 10,000 |
| Total maturities of long-term debt | $ 963,000 |
Derivative Liabilities (Details) |
6 Months Ended |
|---|---|
|
Dec. 31, 2021
USD ($)
| |
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
| Change in derivative liabilities | $ 75,487,522 |
| Fair value of the derivative liability | $ 46,528,773 |
Derivative Liabilities (Details) - Schedule of fair market value of the derivative liability |
6 Months Ended |
|---|---|
Dec. 31, 2021 | |
| Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
| Expected dividend yield | |
| Minimum [Member] | |
| Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
| Risk free interest rate | 0.29% |
| Stock volatility factor | 98.00% |
| Weighted average expected option life | 1 year |
| Maximum [Member] | |
| Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
| Risk free interest rate | 1.26% |
| Stock volatility factor | 200.00% |
| Weighted average expected option life | 5 years |
Marketable Securities (Details) |
6 Months Ended |
|---|---|
|
Dec. 31, 2021
USD ($)
| |
| Investments, Debt and Equity Securities [Abstract] | |
| Interest income | $ 46,980 |
Marketable Securities (Details) - Schedule of cash and short and long-term investments |
Dec. 31, 2021
USD ($)
|
|---|---|
| Short term investments: | |
| Bonds (held-to-maturity) | $ 1,806,513 |
| Long term investments: | |
| Bonds (held-to-maturity) | 6,846,879 |
| Total short and long-term investments | $ 8,653,392 |
Marketable Securities (Details) - Schedule of amortized cost of the held-to-maturity bonds |
Dec. 31, 2021
USD ($)
|
|---|---|
| Marketable Securities (Details) - Schedule of amortized cost of the held-to-maturity bonds [Line Items] | |
| Total | $ 8,653,392 |
| AA/A [Member] | |
| Marketable Securities (Details) - Schedule of amortized cost of the held-to-maturity bonds [Line Items] | |
| Total | 2,629,275 |
| BBB [Member] | |
| Marketable Securities (Details) - Schedule of amortized cost of the held-to-maturity bonds [Line Items] | |
| Total | $ 6,024,117 |
Marketable Securities (Details) - Schedule of gross unrealized gains and losses - Bonds [Member] - Level 2 [Member] |
6 Months Ended |
|---|---|
|
Dec. 31, 2021
USD ($)
| |
| Marketable Securities (Details) - Schedule of gross unrealized gains and losses [Line Items] | |
| Cost | $ 8,653,392 |
| Gross Unrealized Gains | |
| Gross Unrealized Losses | (173,123) |
| Fair Value | $ 8,480,269 |
Commitments and Contingencies (Details) - USD ($) |
Oct. 02, 2021 |
Sep. 01, 2021 |
Dec. 31, 2021 |
|---|---|---|---|
| Commitments and Contingencies Disclosure [Abstract] | |||
| Deposits paid | $ 34,250 | ||
| Research agreement, description | As consideration under the research agreement, the University of Michigan will receive a maximum of $296,448, from the Company. The research agreement may be terminated by either party upon ninety (90) day prior written notice or a material breach or default, which is not cured within 90 days of receipt of a written notice of such breach. This agreement was signed by the Company on September 23, 2021. | the Company entered into a new research agreement with the University of Iowa. As consideration under the research agreement, the University of Iowa will receive a maximum of $350,000 from the Company. The contract period is from September 1, 2021 through August 31, 2022. The research agreement may be terminated by either party upon sixty (60) day prior written notice or a material breach or default, which is not cured within 90 days of receipt of a written notice of such breach. This agreement was signed by the Company on September 13, 2021. As of December 31, 2021, the Company has accrued the amount due of $116,666. |
Related Party (Details) - USD ($) |
1 Months Ended | 6 Months Ended |
|---|---|---|
Jun. 30, 2021 |
Dec. 31, 2021 |
|
| Related Party Transactions [Abstract] | ||
| Salary | $ 211,750 | |
| Current accrual | 14,750 | |
| Accrued expenses | $ 226,500 | |
| Aggregate redeemed option to purchase (in Shares) | 24,887,463 | |
| Stock options to related parties | $ 1,450,000 |
Subsequent Events (Details) - Subsequent Event [Member] - USD ($) |
Jan. 27, 2022 |
Jan. 07, 2022 |
|---|---|---|
| Subsequent Events (Details) [Line Items] | ||
| Issued shares | 200,976,352 | |
| Conversion of principal amount (in Dollars) | $ 135,500 | |
| Accrued interest (in Dollars) | $ 55,428 | |
| Minimum [Member] | ||
| Subsequent Events (Details) [Line Items] | ||
| Common stock shares authorized | 5,000,000,000 | |
| Maximum [Member] | ||
| Subsequent Events (Details) [Line Items] | ||
| Common stock shares authorized | 10,000,000,000 | |
| Series A Preferred Stock [Member] | ||
| Subsequent Events (Details) [Line Items] | ||
| Issued shares | 1,000 | |
| Preferred stock par value (in Dollars per share) | $ 0.001 | |
| Series A Preferred Stock [Member] | Business Combination [Member] | ||
| Subsequent Events (Details) [Line Items] | ||
| Preferred stock voting percentage | 51.00% | |
| Series A Preferred Stock [Member] | Chief Executive Officer [Member] | ||
| Subsequent Events (Details) [Line Items] | ||
| Issued shares | 1,000 |